Opinion|Videos|May 13, 2025
The Role of Novel Targeted Therapies
Author(s)Kathleen Moore, MD, MS
A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.
Advertisement
Episodes in this series
Video content is prompted by the following:
Novel Targeted Therapies in the Treatment Landscape
Key Themes:
- Emergence of antibody-drug conjugates (ADCs) targeting various receptors
- Movement of ADCs into earlier treatment settings
- Biomarker-directed therapy approach
Notable Insights:
- Multiple ADCs are in development with different targeting mechanisms and payloads:
- Mirvetuximab soravtansine (folate receptor alpha, microtubule toxin)
- Renatabart cecitakin (folate receptor alpha, exatecan payload)
- Trastuzumab deruxtecan (HER2, deruxtecan payload)
- Relutagimod deruxtecan (cadherin-6, deruxtecan payload)
- TORL-1-23 (claudin-6, MMAE payload)
- ADCs are moving from platinum-resistant settings into maintenance therapy and frontline treatment:
- GLORIOSA trial: mirvetuximab plus bevacizumab maintenance after second-line platinum
- Trastuzumab deruxtecan trials in HRD-negative frontline maintenance
- Dr Moore emphasized that these are “very effective medications” but acknowledged: “We’re excited, but there’s a lot we have to learn...there’s just going to be quite a bit of work to do in the next years to really sort this out, to optimize for patients.”
Advertisement
Related to this article
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Advertisement
Advertisement
Trending on AJMC
1
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
4
FDA Approves First Treatment for Sanfilippo Syndrome Type A
5